<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="HA2E1524E24884A009FF890D4FC69FE12" public-private="public">
	<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>114 HR 2850 IH: Stop Overdose Stat Act of 2015</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2015-06-23</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">I</distribution-code>
		<congress>114th CONGRESS</congress>
		<session>1st Session</session>
		<legis-num>H. R. 2850</legis-num>
		<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action>
			<action-date date="20150623">June 23, 2015</action-date>
			<action-desc><sponsor name-id="E000290">Ms. Edwards</sponsor> (for herself, <cosponsor name-id="C001083">Mr. Carney</cosponsor>, <cosponsor name-id="C001090">Mr. Cartwright</cosponsor>, <cosponsor name-id="C001101">Ms. Clark of Massachusetts</cosponsor>, <cosponsor name-id="C000714">Mr. Conyers</cosponsor>, <cosponsor name-id="C000984">Mr. Cummings</cosponsor>, <cosponsor name-id="D000216">Ms. DeLauro</cosponsor>, <cosponsor name-id="E000288">Mr. Ellison</cosponsor>, <cosponsor name-id="F000454">Mr. Foster</cosponsor>, <cosponsor name-id="K000375">Mr. Keating</cosponsor>, <cosponsor name-id="L000287">Mr. Lewis</cosponsor>, <cosponsor name-id="L000570">Mr. Ben Ray Luján of New Mexico</cosponsor>, <cosponsor name-id="M001185">Mr. Sean Patrick Maloney of New York</cosponsor>, <cosponsor name-id="M000312">Mr. McGovern</cosponsor>, <cosponsor name-id="M001160">Ms. Moore</cosponsor>, <cosponsor name-id="N000147">Ms. Norton</cosponsor>, <cosponsor name-id="O000170">Mr. O’Rourke</cosponsor>, <cosponsor name-id="P000597">Ms. Pingree</cosponsor>, <cosponsor name-id="R000053">Mr. Rangel</cosponsor>, <cosponsor name-id="R000515">Mr. Rush</cosponsor>, <cosponsor name-id="R000577">Mr. Ryan of Ohio</cosponsor>, <cosponsor name-id="T000469">Mr. Tonko</cosponsor>, <cosponsor name-id="V000128">Mr. Van Hollen</cosponsor>, <cosponsor name-id="W000822">Mrs. Watson Coleman</cosponsor>, <cosponsor name-id="W000800">Mr. Welch</cosponsor>, and <cosponsor name-id="L000551">Ms. Lee</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To prevent deaths occurring from drug overdoses.</official-title>
	</form>
	<legis-body id="H740F5C3C72914AFBB2D6CDC97FEA44B2" style="OLC">
 <section id="H038D3294550C4348A2A7AA4B883A8A8A" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Stop Overdose Stat Act of 2015</short-title></quote>.</text> </section><section id="H752B2BAFB85D43CA8B1BF80135C30889"><enum>2.</enum><header>Findings</header><text display-inline="no-display-inline">Congress finds the following:</text>
 <paragraph id="HDD544BEADC924D4BAB1C75DC0B26A45B"><enum>(1)</enum><text>According to the Centers for Disease Control and Prevention, each day in the United States, more than 100 people die from a drug overdose. Among people 25 to 64 years old, drug overdose causes more deaths than motor vehicle accidents.</text>
 </paragraph><paragraph id="H4487490E6F52495D91A2795C612A14CD"><enum>(2)</enum><text>The Centers for Disease Control and Prevention reports that nearly 44,000 people in the United States died from a drug overdose in 2013 alone. More than 80 percent of those deaths were due to unintentional drug overdoses, and many could have been prevented.</text>
 </paragraph><paragraph id="H3C1350AB3C7741AAAEC0748AA9DDA654"><enum>(3)</enum><text>Deaths resulting from unintentional drug overdoses increased more than 300 percent between 1980 and 1998, and more than tripled between 1999 and 2013.</text>
 </paragraph><paragraph id="HF514665E52114597B9BED0E2EDC8DB05"><enum>(4)</enum><text>Nearly 92 percent of all unintentional poisoning deaths are due to drugs. Since 1999, in the United States the population of non-Hispanic Whites and the population of Indians (as defined in section 4 of the Indian Self-Determination and Education Assistance Act (<external-xref legal-doc="usc" parsable-cite="usc/25/450b">25 U.S.C. 450b</external-xref>)) have seen the highest rates of unintentional drug poisoning deaths.</text>
 </paragraph><paragraph id="H76F9DE3BAFCB4F47BD36C09CCAE6D2AC"><enum>(5)</enum><text>Opioid medications such as oxycodone and hydrocodone were involved in nearly 46 percent of all unintentional drug poisoning deaths in 2013.</text>
 </paragraph><paragraph id="HFE85D761E90E43E7BFCA04192C93DC46"><enum>(6)</enum><text>Unintentional drug poisoning deaths involving heroin nearly tripled between 2010 and 2013 and were 23 percent of all unintentional drug poisoning deaths in 2013.</text>
 </paragraph><paragraph id="H5D1A14B1730944F89DA3ADCD062694C3"><enum>(7)</enum><text>Between 1999 and 2010, opioid medication overdose fatalities increased by more than 400 percent among women and 265 percent among men.</text>
 </paragraph><paragraph id="H2E11E72B69614057B474BD44FFE8110F"><enum>(8)</enum><text>Military veterans are at elevated risk of experiencing a drug overdose. Veterans who served in Vietnam, Iraq, or Afghanistan and who have combat injuries, posttraumatic stress disorder, and other co-occurring mental health diagnoses are at elevated risk of fatal drug overdose from opioid medications.</text>
 </paragraph><paragraph id="H50191CBCC69C4A148C6E8FC55BCA0837"><enum>(9)</enum><text>Rural and suburban regions are disproportionately affected by opioid medication and heroin overdoses. From 2000 through 2013, the age-adjusted rate for drug poisoning deaths involving heroin has increased nearly 11-fold in the Midwest region and more than 3-fold in the South region.</text>
 </paragraph><paragraph id="H5AB47F4FB11441428B84B9B3E31CB645"><enum>(10)</enum><text>Urban centers also continue to struggle with overdose, which is the leading cause of death among homeless adults.</text>
 </paragraph><paragraph id="HE88C6E8633174C66BCA451938D4205B2"><enum>(11)</enum><text>In 2009 alone, estimated lost productivity and direct medical costs from opioid medication poisonings exceeded $20,000,000,000.</text>
 </paragraph><paragraph id="H98165202823440F9BCCE0C5024840996"><enum>(12)</enum><text>Opioid medication poisonings cost health insurers an estimated $72,000,000,000 annually in medical costs.</text>
 </paragraph><paragraph id="H6F6C44E522F7496F867215936C40DFB3"><enum>(13)</enum><text>Both fatal and nonfatal overdoses place a heavy burden on public health and public safety resources, yet there is no coordinated cross-Federal agency response to prevent overdose fatalities.</text>
 </paragraph><paragraph id="H9963E4CA56F44E308CE4A3255044EAEE"><enum>(14)</enum><text>Naloxone is a medication that rapidly reverses overdose from heroin and opioid medications.</text> </paragraph><paragraph id="HE6CFD55BEADE4FB599D785C705F9CCD5"><enum>(15)</enum><text>Naloxone has no pharmacological effect if administered to a person who has not taken opioids and has no potential for abuse. Naloxone provides additional time to obtain necessary medical assistance during an overdose.</text>
 </paragraph><paragraph id="H2A5970D1CA3E46C59F2D880144D59E98"><enum>(16)</enum><text>Lawmakers in Arkansas, California, Colorado, Connecticut, Delaware, Georgia, Idaho, Illinois, Indiana, Kentucky, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Nevada, New Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, Tennessee, Utah, Vermont, Virginia, Washington, West Virginia, Wisconsin, and the District of Columbia have removed legal impediments to increasing naloxone prescription and its use by bystanders who are in a position to respond to an overdose.</text>
 </paragraph><paragraph id="H23675E9458ED4628857BCA2BBEF611A6"><enum>(17)</enum><text>The American Medical Association and the American Public Health Association support further implementation of community-based programs that offer naloxone and other opioid overdose prevention services.</text>
 </paragraph><paragraph id="HD37A540AEBAE4427BE1E67DD18D21EAA"><enum>(18)</enum><text>Community-based overdose prevention programs have successfully prevented deaths from opioid overdoses by making rescue training and naloxone available to first responders, parents, and other bystanders who may encounter an overdose. A study funded by the Centers for Disease Control and Prevention of community-based overdose prevention programs provided by the Massachusetts Department of Public Health found that communities with access to overdose prevention programs experienced lower mortality rates from opioid overdoses than communities that did not have access to overdose prevention programs during the study period.</text>
 </paragraph><paragraph id="H8C1718A0583A422A9AA5FAEB9DED6D01"><enum>(19)</enum><text display-inline="yes-display-inline">Over 150,000 potential bystanders have been trained by overdose prevention programs in the United States. A Centers for Disease Control and Prevention report credits overdose prevention programs with reversing more than 26,000 overdoses since 1996.</text>
 </paragraph><paragraph id="H8C0C011C7BE24CE3B4DD8E25A6E1EA93"><enum>(20)</enum><text display-inline="yes-display-inline">At least 188 local overdose prevention programs are operating in the United States, including in major cities such as Baltimore, Chicago, Los Angeles, New York City, Boston, San Francisco, and Philadelphia, and statewide in New Mexico, Massachusetts, and New York. Between December 2007 and March 2014, overdose prevention programs facilitated by the Massachusetts Department of Public Health trained more than 22,500 people who reported more than 2,655 rescues. Since 2004, a program administered by the Baltimore City Health Department has trained more than 11,000 people who reported more than 220 rescues. Project Lazarus, an overdose prevention program in Wilkes County, North Carolina, reduced overdose deaths 69 percent between 2009 and 2011.</text>
 </paragraph><paragraph id="H8BC98F4339E54AB5A15FAB1E6BA2E394"><enum>(21)</enum><text>In Illinois, the Department of Human Services, Division of Alcoholism and Substance Abuse has enrolled over 20 drug overdose prevention programs with over 100 designated sites across Illinois targeting multiple service populations. These enrollees include police departments, county health departments, medical facilities, licensed substance abuse treatment programs, and community organizations. Statewide, over 2,000 police officers and more than 600 others have been trained thus far. The DuPage County Illinois Health Department has trained over 1,200 police officers and has reported 34 overdose reversals in 2014 alone.</text>
 </paragraph><paragraph id="HA781A06A72D14DD1BD082197F3577519"><enum>(22)</enum><text>The Office of National Drug Control Policy supports equipping first responders to help reverse overdoses. Police officers on patrol in Quincy, Massachusetts, have conducted 300 overdose rescues with naloxone since 2011. The police department has reported a 95-percent success rate with overdose rescue attempts by police officers. In Suffolk County, New York, police officers have saved more than 563 lives with naloxone in 2013 alone.</text>
 </paragraph><paragraph id="HE3F85EA7F1DF4B2F882EEDCE758A0E5D"><enum>(23)</enum><text>Research shows that the cost per year of life gained by making naloxone available to reverse overdoses is within the range of what people in the United States usually pay for health treatments.</text>
 </paragraph><paragraph id="HFDA6D3B3751147AD9912DAD78332ABE1"><enum>(24)</enum><text>Prompt administration of naloxone and provision of emergency care by a bystander can reduce health complications and health care costs that arise when a person is deprived of oxygen for an extended period of time.</text>
 </paragraph><paragraph id="H11C10857D3B24131A292090DC3BA6D2B"><enum>(25)</enum><text>Overdose prevention programs are needed in correctional facilities, addiction treatment programs, and other places where people are at higher risk of overdosing after a period of abstinence.</text>
 </paragraph><paragraph id="H00A8F9B477864C5AA3833843A4A4E8AB"><enum>(26)</enum><text>Timely, drug-specific fatal and nonfatal surveillance data at the local, State, and regional level is critically needed to target prevention efforts.</text>
 </paragraph><paragraph id="H0C96D9D184884F91A1C7992FEB72057D"><enum>(27)</enum><text>People affected by drug overdose gather on August 31 of each year in communities nationwide for Overdose Awareness Day, to mourn and pay tribute to loved ones and raise awareness about overdose risk and prevention.</text>
 </paragraph></section><section id="HCBD96BC4FBB64E07ACCD8599F89D6B90"><enum>3.</enum><header>Overdose prevention programs</header><text display-inline="no-display-inline">Title III of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/241">42 U.S.C. 241 et seq.</external-xref>) is amended by adding at the end the following:</text>
			<quoted-block display-inline="no-display-inline" id="H334D670CA759426B9D7AB69EB53664D6" style="OLC">
				<part id="HF515D1D99C224F28B054198F10762438" style="OLC"><enum>W</enum><header>Overdose prevention programs</header>
					<section id="H7BD4BEA4F3EB482BB57BDCAE38AE5CFA"><enum>399OO.</enum><header>Cooperative agreement program to reduce drug overdose deaths</header>
 <subsection id="H5CF7C8CB0993423BABE0F8E3BAC458F5"><enum>(a)</enum><header>Program authorized</header><text>The Secretary, acting through the Administrator of the Substance Abuse and Mental Health Services Administration, shall enter into cooperative agreements with eligible entities to enable the eligible entities to reduce deaths occurring from overdoses of drugs.</text>
 </subsection><subsection id="HB88F396BC7F34B9BA43F654D21D69ABD"><enum>(b)</enum><header>Eligible entities</header><text>To be eligible to receive a cooperative agreement under this section, an entity shall be a State, local, or tribal government, a correctional institution, a law enforcement agency, a community agency, a professional organization in the field of poison control and surveillance, or a private nonprofit organization.</text>
						</subsection><subsection id="H4992B06E712A4BC9945B22DF1B9425AD"><enum>(c)</enum><header>Application</header>
 <paragraph id="H6F9B0F0DB3934F87A6C08069D6973D06"><enum>(1)</enum><header>In general</header><text>An eligible entity desiring a cooperative agreement under this section shall submit to the Secretary an application at such time, in such manner, and containing such information as the Secretary may require.</text>
 </paragraph><paragraph id="H6A5E94C13B5343A992D18EDB5A752588"><enum>(2)</enum><header>Contents</header><text>An application under paragraph (1) shall include—</text> <subparagraph id="HE63730AB6C854BF2AD035F6879CF6D09"><enum>(A)</enum><text>a description of the activities to be funded through the cooperative agreement; and</text>
 </subparagraph><subparagraph id="H64BD140E5AFF449C9B881892DAF9518C"><enum>(B)</enum><text>evidence that the eligible entity has the capacity to carry out such activities.</text> </subparagraph></paragraph></subsection><subsection id="H96EBA67107F44F078C967FBC5CE4AC77"><enum>(d)</enum><header>Priority</header><text>In entering into cooperative agreements under subsection (a), the Secretary shall give priority to eligible entities that—</text>
 <paragraph id="H40774AC6DF254D3F9195D605E739D940"><enum>(1)</enum><text>are a public health agency or community-based organization; and</text> </paragraph><paragraph id="HFDB6D28BC87B45F58462B33A48BE47D7"><enum>(2)</enum><text>have expertise in preventing deaths occurring from overdoses of drugs in populations at high risk of such deaths.</text>
 </paragraph></subsection><subsection id="HEED81AB51F844208A43E00DA50FE5E88"><enum>(e)</enum><header>Eligible activities</header><text>As a condition of receipt of a cooperative agreement under this section, an eligible entity shall agree to use the cooperative agreement to do each of the following:</text>
 <paragraph id="H1BFDCE8635104327992E92834F2D7191"><enum>(1)</enum><text>Purchase and distribute the drug naloxone or a similarly effective medication.</text> </paragraph><paragraph id="HC40F3CBE86CE4AA681FB9B99C77C7796"><enum>(2)</enum><text>Carry out one or more of the following activities:</text>
 <subparagraph id="H00DDCB84F2C74B9E92E84664C7E1EF61"><enum>(A)</enum><text display-inline="yes-display-inline">Educating prescribers and pharmacists about overdose prevention and naloxone prescription, or prescriptions of a similarly effective medication.</text>
 </subparagraph><subparagraph id="HF0C926BC6DD64887978446CB253973DE"><enum>(B)</enum><text display-inline="yes-display-inline">Training first responders, other individuals in a position to respond to an overdose, and law enforcement and corrections officials on the effective response to individuals who have overdosed on drugs. Training pursuant to this subparagraph may include any activity that is educational, instructional, or consultative in nature, and may include volunteer training, awareness building exercises, outreach to individuals who are at-risk of a drug overdose, and distribution of educational materials.</text>
 </subparagraph><subparagraph id="H90655A1E98544B939A571F5F474B7674"><enum>(C)</enum><text>Implementing and enhancing programs to provide overdose prevention, recognition, treatment, and response to individuals in need of such services.</text>
 </subparagraph><subparagraph commented="no" id="H18B92583605D4024A87FC2A00B5ADDD3"><enum>(D)</enum><text>Educating the public and providing outreach to the public about overdose prevention and naloxone prescriptions, or prescriptions of other similarly effective medications.</text>
								</subparagraph></paragraph></subsection><subsection commented="no" id="H5254589E2744438FACF70C021861C9C3"><enum>(f)</enum><header>Coordinating center</header>
 <paragraph commented="no" id="H0AB7AE64C23B4839824ECE03FB16B619"><enum>(1)</enum><header>Establishment</header><text>The Secretary shall establish and provide for the operation of a coordinating center responsible for—</text>
 <subparagraph commented="no" id="H41F43C8CFDD04ADC8EF99B5E1F318EFB"><enum>(A)</enum><text>collecting, compiling, and disseminating data on the programs and activities under this section, including tracking and evaluating the distribution and use of naloxone and other similarly effective medication;</text>
 </subparagraph><subparagraph commented="no" id="H520539DF5A0149E1949E6FF2846FA3BB"><enum>(B)</enum><text display-inline="yes-display-inline">evaluating such data and, based on such evaluation, developing best practices for preventing deaths occurring from drug overdoses;</text>
 </subparagraph><subparagraph commented="no" id="H3C59308B96EE4FD480858CA5384D615F"><enum>(C)</enum><text>making such best practices specific to the type of community involved;</text> </subparagraph><subparagraph commented="no" id="HC3DAF36115F54DA6A94525714C958DA4"><enum>(D)</enum><text>coordinating and harmonizing data collection measures;</text>
 </subparagraph><subparagraph id="H9051C1B73D7B4C93B3BF9CF5270113BA"><enum>(E)</enum><text>evaluating the effects of the program on overdose rates; and</text> </subparagraph><subparagraph id="HC543A140E7A24F0BA93ED909643E26BB"><enum>(F)</enum><text>education and outreach to the public about overdose prevention and prescription of naloxone and other similarly effective medication.</text>
 </subparagraph></paragraph><paragraph commented="no" id="H966B908762CE4AB5BD85C7E1FBC022B5"><enum>(2)</enum><header>Reports to center</header><text>As a condition on receipt of a cooperative agreement under this section, an eligible entity shall agree to prepare and submit, not later than 90 days after the end of the cooperative agreement period, a report to such coordinating center and the Secretary describing the results of the activities supported through the cooperative agreement.</text>
 </paragraph></subsection><subsection commented="no" id="H6404D1C809644F0EB54D7EDBEB5C85A0"><enum>(g)</enum><header>Duration</header><text display-inline="yes-display-inline">The period of a cooperative agreement under this section shall be 4 years.</text> </subsection><subsection id="HF5997A16EE064E01BFD593306631BDB7"><enum>(h)</enum><header>Definition</header><text>In this part, the term <term>drug</term> —</text>
 <paragraph id="H0CCBD420379846098A0DD9409AB8EFED"><enum>(1)</enum><text>means a drug, as defined in section 201 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/321">21 U.S.C. 321</external-xref>); and</text>
 </paragraph><paragraph id="H52AF7A911DA24C489904912B83D17750"><enum>(2)</enum><text>includes controlled substances, as defined in section 102 of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/802">21 U.S.C. 802</external-xref>).</text>
 </paragraph></subsection><subsection id="H203973090C3D4458931C4072058FDD18"><enum>(i)</enum><header>Authorization of appropriations</header><text>There are authorized to be appropriated $20,000,000 to carry out this section for each of the fiscal years 2016 through 2020.</text>
						</subsection></section><section id="HC08205F4C23941B484C2F5E21EECE053"><enum>399OO–1.</enum><header>Surveillance capacity building</header>
 <subsection id="HD3B58CE73CA74159A01FBB26FB3AB543"><enum>(a)</enum><header>Program authorized</header><text>The Secretary, acting through the Director of the Centers for Disease Control and Prevention, shall award cooperative agreements to eligible entities to improve fatal and nonfatal drug overdose surveillance and reporting capabilities, including—</text>
 <paragraph id="H0D41374F18A5493DB5F8FD869706DDD8"><enum>(1)</enum><text>providing training to improve identification of drug overdose as the cause of death by coroners and medical examiners;</text>
 </paragraph><paragraph id="H5C95342FB9704465B5125FDD0701C91D"><enum>(2)</enum><text>establishing, in cooperation with the National Poison Data System, coroners, and medical examiners, a comprehensive national program for surveillance of, and reporting to an electronic database on, drug overdose deaths in the United States; and</text>
 </paragraph><paragraph id="HB64E6A3CEF42489EAE60C0603B3A7208"><enum>(3)</enum><text>establishing, in cooperation with the National Poison Data System, a comprehensive national program for surveillance of, and reporting to an electronic database on, fatal and nonfatal drug overdose occurrences, including epidemiological and toxicologic analysis and trends.</text>
 </paragraph></subsection><subsection id="H8AC5E1C849484A88AA367F1F0DCD3173"><enum>(b)</enum><header>Eligible entity</header><text>To be eligible to receive a cooperative agreement under this section, an entity shall be—</text> <paragraph id="H52AB0563CDE84BC4B7ADCAADC9BF42B2"><enum>(1)</enum><text>a State, local, or tribal government; or</text>
 </paragraph><paragraph id="HB8109EB541D3438ABD78537D330EA325"><enum>(2)</enum><text>the National Poison Data System working in conjunction with a State, local, or tribal government.</text> </paragraph></subsection><subsection id="H0A5F2E2BED994B90B5253A76722A13A3"><enum>(c)</enum><header>Application</header> <paragraph id="HAED3EC3E69C9479CA27DF78734B0386C"><enum>(1)</enum><header>In general</header><text>An eligible entity desiring a cooperative agreement under this section shall submit to the Secretary an application at such time, in such manner, and containing such information as the Secretary may require.</text>
 </paragraph><paragraph id="H9096D59C02FF4D85A3A138272A4879AB"><enum>(2)</enum><header>Contents</header><text>The application described in paragraph (1) shall include—</text> <subparagraph id="H4D1A6E2784274966B0D761DE6668672F"><enum>(A)</enum><text>a description of the activities to be funded through the cooperative agreement; and</text>
 </subparagraph><subparagraph id="H5F9239582F4B43C9BFA33887DE207A58"><enum>(B)</enum><text>evidence that the eligible entity has the capacity to carry out such activities.</text> </subparagraph></paragraph></subsection><subsection id="HA7455EFCE3FD42B4B81D14A04C189C69"><enum>(d)</enum><header>Report</header><text>As a condition of receipt of a cooperative agreement under this section, an eligible entity shall agree to prepare and submit, not later than 90 days after the end of the cooperative agreement period, a report to the Secretary describing the results of the activities supported through the cooperative agreement.</text>
 </subsection><subsection id="HB2858D07826049AFB0C3C94F450D99F6"><enum>(e)</enum><header>National poison data system</header><text>In this section, the term <term>National Poison Data System</term> means the system operated by the American Association of Poison Control Centers, in partnership with the Centers for Disease Control and Prevention, for real-time local, State, and national electronic reporting, and the corresponding database network.</text>
 </subsection><subsection id="HB8BE84EF67D545EEA1C281D1BEB1529B"><enum>(f)</enum><header>Authorization of appropriations</header><text>There are authorized to be appropriated to carry out this section $5,000,000 for each of the fiscal years 2016 through 2020.</text>
						</subsection></section><section id="HA08CC616B3324F0BB7FC902B3C15B664"><enum>399OO–2.</enum><header>Reducing overdose deaths</header>
 <subsection id="HD3049AF49F284D34BF433E1F26A75ED4"><enum>(a)</enum><header>Prevention of drug overdose</header><text>Not later than 180 days after the date of the enactment of this section, the Secretary, in consultation with a task force comprised of stakeholders, shall develop a plan to reduce the number of deaths occurring from overdoses of drugs and shall submit the plan to Congress. The plan shall include—</text>
 <paragraph id="HE28D31AC03AB4D5F807EECD505BD2ECB"><enum>(1)</enum><text>a plan for implementation of a public health campaign to educate prescribers and the public about overdose prevention and prescription of naloxone and other similarly effective medication;</text>
 </paragraph><paragraph id="HC165DC6FF2864CD987B941930C01B183"><enum>(2)</enum><text>recommendations for improving and expanding overdose prevention programming; and</text> </paragraph><paragraph id="H04A41D33363D4307ADDCB41D17CC4A71"><enum>(3)</enum><text>recommendations for such legislative or administrative action as the Secretary determines appropriate.</text>
							</paragraph></subsection><subsection id="H534660FA6622435BBA1C0098CF33001E"><enum>(b)</enum><header>Task force representation</header>
 <paragraph id="H01F18BAFA0A549EA81D8F770937F7B4E"><enum>(1)</enum><header>Required members</header><text>The task force under subsection (a) shall include at least one representative of each of the following:</text>
 <subparagraph id="H0E2F5DC1A92B4E679256CCC14613BFEF"><enum>(A)</enum><text>Individuals directly impacted by drug overdose.</text> </subparagraph><subparagraph id="HB3506EE7F2B34A059881D5E94BE7F25C"><enum>(B)</enum><text>Direct service providers who engage individuals at risk of a drug overdose.</text>
 </subparagraph><subparagraph id="HFD4CD5CC57BF49899629CD0A64B404B1"><enum>(C)</enum><text>Drug overdose prevention advocates.</text> </subparagraph><subparagraph id="H4658EC1497B44A1291D0FD1BF1CB7B42"><enum>(D)</enum><text>The National Institute on Drug Abuse.</text>
 </subparagraph><subparagraph id="H0FDD222170674490BE92B1EE6F9580E4"><enum>(E)</enum><text>The Center for Substance Abuse Treatment.</text> </subparagraph><subparagraph id="H42049AE4BC6149CA926661170A14400D"><enum>(F)</enum><text>The Centers for Disease Control and Prevention.</text>
 </subparagraph><subparagraph id="HE9C5298E50BB4BFF9AE73B81035E1526"><enum>(G)</enum><text>The Health Resources and Services Administration.</text> </subparagraph><subparagraph id="H07783F6EF42F4E34A1BD8C1C0D42F54F"><enum>(H)</enum><text>The Food and Drug Administration.</text>
 </subparagraph><subparagraph id="H9A0D3D6731EC494D8E8336154B96C0CB"><enum>(I)</enum><text display-inline="yes-display-inline">The Office of National Drug Control Policy.</text> </subparagraph><subparagraph id="HF16A6E71E3A44ECB973357B656A4EDB0"><enum>(J)</enum><text display-inline="yes-display-inline">The American Medical Association.</text>
 </subparagraph><subparagraph id="H55FA40BF39854476BC2FAD3695336917"><enum>(K)</enum><text display-inline="yes-display-inline">The American Association of Poison Control Centers.</text> </subparagraph><subparagraph id="HADF45B163F7447DFB4A1EC617C13BF16"><enum>(L)</enum><text>The Federal Bureau of Prisons.</text>
 </subparagraph><subparagraph id="H1F12EF1474A8498FADCF85FA787CF082"><enum>(M)</enum><text>The Centers for Medicare &amp; Medicaid Services.</text> </subparagraph><subparagraph id="H407F78EA9C0D426386B41EA6FF096DD2"><enum>(N)</enum><text>The Department of Justice.</text>
 </subparagraph><subparagraph id="H331F88FDABB94970B4A968AF307EBFBF"><enum>(O)</enum><text>The Department of Defense.</text> </subparagraph><subparagraph id="H91594C04845842388B3BCE66F03E921E"><enum>(P)</enum><text>The Department of Veterans Affairs.</text>
 </subparagraph><subparagraph id="HD403F1490CE94320A08D084B65384601"><enum>(Q)</enum><text>First responders.</text> </subparagraph><subparagraph id="HDFEC4001554E41A986B679B52CBA57C2"><enum>(R)</enum><text>Law enforcement.</text>
 </subparagraph><subparagraph id="H8C1A9CF55696406AB9F67F0ADCAF6F64"><enum>(S)</enum><text>State agencies responsible for drug overdose prevention.</text> </subparagraph></paragraph><paragraph id="H7C23C9CAA6B94B52ADB3C3A8C3FF0444"><enum>(2)</enum><header>Additional members</header><text>In addition to the representatives required by paragraph (1), the task force under subsection (a) may include other individuals with expertise relating to drug overdoses or representatives of entities with expertise relating to drug overdoses, as the Secretary determines appropriate.</text></paragraph></subsection></section></part><after-quoted-block>.</after-quoted-block></quoted-block>
 </section><section id="H1881092EE4534BA5BD7A01AEC88DC685"><enum>4.</enum><header>Overdose prevention research</header><text display-inline="no-display-inline">Subpart 15 of part C of title IV of the Public Health Service Act (<external-xref legal-doc="usc" parsable-cite="usc/42/285o">42 U.S.C. 285o et seq.</external-xref>) is amended by adding at the end the following:</text>
			<quoted-block display-inline="no-display-inline" id="H05F7B43D67224972AC43760411A48AC0" style="OLC">
				<section id="HA6FD07367854453C82521016D2FA7E7D"><enum>464Q.</enum><header>Overdose prevention research</header>
 <subsection id="H02C0B8BF869F4FABA8375836A1DA255A"><enum>(a)</enum><header>Overdose research</header><text>The Director of the Institute shall prioritize and conduct or support research on drug overdose and overdose prevention. The primary aims of this research shall include—</text>
 <paragraph id="H02506E1A94B947AB88080C1B382134FF"><enum>(1)</enum><text>an examination of circumstances that contribute to drug overdose and identification of drugs associated with fatal overdose;</text>
 </paragraph><paragraph id="HB1735F7D1EA344BAA425A4E1E3475B77"><enum>(2)</enum><text>an evaluation of existing overdose prevention methods;</text> </paragraph><paragraph id="HEE0419F14A084F4490DF4CDFEB437E71"><enum>(3)</enum><text display-inline="yes-display-inline">pilot programs or research trials on new overdose prevention strategies or programs that have not been studied in the United States;</text>
 </paragraph><paragraph id="H403850C4899246C4A056DFA534C77606"><enum>(4)</enum><text>scientific research concerning the effectiveness of overdose prevention programs, including how to effectively implement and sustain such programs;</text>
 </paragraph><paragraph id="H7D89D9EFFA0F4142B0B6C587D10257BE"><enum>(5)</enum><text>comparative effectiveness research of model programs; and</text> </paragraph><paragraph id="H3D41124718A0412489C752827A8D652E"><enum>(6)</enum><text>implementation of science research concerning effective overdose prevention programming examining how to implement and sustain overdose prevention programming.</text>
 </paragraph></subsection><subsection id="H6F9F0A70E9F14DD4AD3CD53325DFE0FF"><enum>(b)</enum><header>Formulations of naloxone</header><text>The Director of the Institute shall support research on the development of formulations of naloxone, and other similarly effective medications, and dosage delivery devices specifically intended to be used by lay persons or first responders for the prehospital treatment of unintentional drug overdose.</text>
 </subsection><subsection id="H55DA4CAA64664B1BBA059AE9C874E8A5"><enum>(c)</enum><header>Definition</header><text>In this section, the term <term>drug</term> has the meaning given such term in section 399OO.</text> </subsection><subsection id="H809FCBD9B99141AC8809177384DFD735"><enum>(d)</enum><header>Authorization of appropriations</header><text>There are authorized to be appropriated to carry out this section $5,000,000 for each of the fiscal years 2016 through 2020.</text></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block>
		</section></legis-body>
</bill>


